chartexchange

Can This Pharma Company Capture a Larger Share of Multi-Billion-Dollar Respiratory Market Through Partnerships?

Trade Brains | Nov 14, 2026 9:30 AM EST

Aurobindo Pharma is tapping the multi-billion-dollar respiratory market through generic launches, partnerships and in-house products. This article explores whether these initiatives can strengthen its US presence and drive future growth. The opportunity is significant, but the key question is how quickly Aurobindo can convert its development pipeline and partnerships into commercial sales.
Market Opportunity
Aurobindo’s respiratory ambitions gained momentum during Q2 FY27, when management highlighted the multi-billion-dollar potential of the inhalation market. It also indicated that one of its partnered products represents significant commercial value and that even a reasonable market share could generate meaningful business for the company.
The opportunity comes at a time when Aurobindo’s US business is already expanding. US revenue increased 25% year-on-year to ₹4,555 crore, equivalent to $477 million, in Q2 FY27. Consolidated revenue reached a record ₹10,263 crore, up 24%, while operating EBITDA grew 28% to ₹2,156 crore, with a margin of 21%.

Also read: EMS Limited Q2: Profit Up 51% QoQ as 9 New Water and Sewerage Wins Lift Order Book to ₹3,153 Crore

The company also launched 10 products in the US, filed seven ANDAs and received 12 final approvals during the quarter. This provides a broader platform for commercialising differentiated products, including respiratory therapies.
Advair and QVAR
The company has already made some significant progress in this regard, having launched two respiratory products. Generic Advair was launched in the United States in Q2 FY27, while generic QVAR was approved by the FDA. This progress is essential, as it helps the firm to be better positioned in complicated inhalation products due to technical and regulatory challenges.
It is especially crucial in case of the launch of the Advair product, since management said that the product was launched in the middle of the quarter, which means that all revenues generated by this product were not included in Q2 figures.
Generic QVAR was also approved, but management did not provide any information about launch date and financial results of this activity during the conference call.
Partnership Pipeline
Partnerships form yet another component of Aurobindo’s respiratory business plan. Management disclosed that a single partner inhalation product was launched commercially in Q2 FY27. Although the launch was at an initial stage, the company foresees volume and better business contribution going forward in the next few quarters.
Aurobindo has also entered into partnership with a leading pharma firm for one future respiratory product. In addition, it is in talks with other industry participants about potential collaborations and in-licensing deals with some already in an advanced stage.

Also read: 8 Small-Cap Stocks With PEG and Debt-to-Equity Ratios Below 1 to Keep on Your Radar

Management, however, did not reveal the identity of these partners and revenue estimates on a product basis. But from management’s disclosure, it can be inferred that the company wants to diversify its respiratory portfolio via internal developments and partnerships, and not just via one product.
In-House Pipeline
Alongside partnerships, Aurobindo is developing its own inhalation portfolio. Management confirmed that one in-house metered-dose inhaler (MDI) product has already received approval, with preparations for manufacturing and commercialisation underway.
More importantly, the company has at least four additional inhalation products under development at different stages. While individual product names and launch timelines were not disclosed, this pipeline could support a staggered expansion of its respiratory portfolio.
Management indicated that some products could contribute in the short to medium term, while others remain at the development stage or depend on loss-of-exclusivity events. This means the commercial opportunity is likely to build progressively rather than materialise all at once.
Raleigh Facility
Manufacturing capability will be critical to converting these opportunities into revenue. Aurobindo’s Raleigh facility in North Carolina recently received a VAI classification, supporting the regulatory pathway for additional filings and approvals in respiratory, transdermal and dermal products.

Also read: Bank of Baroda FD Rate Hiked to 7.45%: ₹10 Lakh Investment Earns Up to ₹1.18 Lakh Interest in 555 Days - Check Details

However, current utilisation remains nominal because MDI manufacturing has not started. The facility currently manufactures only one relatively small dermatology product. Management expects utilisation to improve over the next six to nine months as additional products move towards commercial production.
The pace of improvement will depend on manufacturing readiness, regulatory progress and product demand. Therefore, the VAI classification is an important step, but the next milestone will be translating the facility's capabilities into commercial output.
Could FY29 mark a scale-up phase?
Aurobindo’s respiratory business is expected to develop in stages. Management indicated that a reasonable number of products could be added over the next 18–24 months, while certain larger opportunities may take more than 18 months because of development requirements and loss-of-exclusivity timelines.
During the call, management also agreed that a more scaled-up respiratory business around mid-FY29 was a possibility, subject to product and market conditions. This is an indicative timeline, not a firm revenue target.

Also read: Sensex & Nifty 50 | Stock Market Live Updates Today: Nifty Falls 0.35%, Sensex Slips 0.19%; IT and Energy Stocks Gain

Overall, Aurobindo has several growth levers in place: generic Advair has been launched, QVAR has been approved, one partnered inhalation product is commercial, another partnership is in the pipeline, and at least four additional products are under development.
The next test will be execution-converting these opportunities into sustained sales while improving manufacturing utilisation. If the company delivers on these milestones, respiratory could become a more meaningful contributor to its US business over the coming years.

Read original article